APPENDICES. A systematic review and economic model of the ...

Study Intervention Participants Outcomes
Core symptoms
Abbreviated CTRS: total score
On-task behaviour
Arm 1
MPH
5 mg administered once daily
(Administered by parent)
Reference
DuPaul and Rapport,
1993 49
Co-existent problems
Not reported
Source
CCOHTA Report
Educational performance
Academic efficiency score
Arm 2
MPH
10 mg
(Administered by parent)
Setting
USA
Psychological function
Not reported
Inclusion criteria
1. Diagnosis using DSM-III criteria
2. Problem behaviours in at least 50% of situations on the Home
Situations Questionnaire
3. Two SDs above the mean on the Werry–Weiss–Peters Activity
Scale
4. Abbreviated CTRS >15
5. Performance on the Matching Familiar Figures Test
characteristic of a ‘fast–inaccurate’ responder
6. Absence of any gross neurological, sensory or motor
impairment
Arm 3
MPH
15 mg
(Administered by parent)
Design
Crossover trial
Depression or anxiety
Not reported
Quality of life
Not reported
Diagnostic criteria
DSM-III
Number
Total randomised = 31 (male = 26)
No withdrawals reported
The study also involved a normal control group of 25 children
Arm 4
MPH
20 mg
(Administered by parent)
Duration
6 weeks; Each dosage
was given for 6 days,
followed by one
washout day
Adverse events
Not reported
Additional outcomes
Not reported
Age
8.12 years (mean); 6–11 years (range); 1.18 years (SD)
Arm 5
Placebo
(Administered by parent)
Purpose
To examine the degree
to which a wide range
of MPH dosages affect
classroom behaviour
and academic
functioning in children
with ADD
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
IQ
Not reported
Health Technology Assessment 2006; Vol. 10: No. 23
Co-morbid disorders
Not reported
Diagnostic subtypes
Not reported
Additional information
No relevant information reported
239